4 assets in Esthesioneuroblastoma

Therapeutic assets addressing Esthesioneuroblastoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Oxodotreotide Esthesioneuroblastoma	National Cancer Institute (NCI)	P1/2	CCC (52)
Olaparib Esthesioneuroblastoma	Fundación de investigación HM	P1/2	CC (47)
Tarlatamab Esthesioneuroblastoma	University of Arizona	P1/2	CC (47)
[212pb]vmt-alpha-net Esthesioneuroblastoma	National Cancer Institute (NCI)	P1	CC (43)